CureVac: Positive Data on Joint COVID-19 and Flu mRNA Vaccine Development Programs

 

• Promising COVID-19 and flu modified mRNA vaccine candidates identified based on positive preliminary data from ongoing Phase 1 studies

• All candidates use CureVac's advanced second-generation mRNA backbone optimized to achieve improved mRNA translation and strong immune responses at low doses

• The preliminary results provide strong evidence of technology for CureVac's mRNA platform; CureVac and partner GSK plan to advance modified mRNA COVID-19 and flu candidates to the next stages of clinical development

• COVID-19: monovalent modified mRNA vaccine candidate CV0501, encoding Omicron variant BA.1, successfully boosted antibody titers against BA.1 and the wild type variants and was generally well tolerated across all tested dose groups

• Flu: monovalent modified mRNA vaccine candidate Flu-SV-mRNA successfully boosted antibody titers against matching flu strain; even at lowest dose, titers were at least in line with a licensed comparator; Flu-SV-mRNA was well tolerated across all tested dose groups

• CureVac to host a webcast and conference call on January 6, 2023 at 3:00 p.m. CET / 9:00 a.m. EST. Access via the Investor Relations section of the CureVac homepage

CureVac will host a webcast and conference call on Friday, January 6, 2023 at 3:00 p.m. CET / 9:00 a.m. EST. The live conference call dial-in details and webcast link can be accessed via the Investor Relations section of the CureVac homepage at https://www.curevac.com/en/newsroom/events/

Corresponding presentation slides will be posted shortly before the start of the webcast. A replay will be made available at this website after the event.

https://finance.yahoo.com/news/curevac-announces-positive-data-joint-121500637.html